Literature DB >> 20030737

Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat.

Frederic Mouquet1, Delphine Rousseau, Valerie Domergue-Dupont, Alain Grynberg, Ronglih Liao.   

Abstract

Trimetazidine (TMZ), a partial inhibitor of fatty acid oxidation, has been effective in treating chronic angina, but its effects on the development of post-myocardial infarction (MI) left ventricular remodeling are not defined. In this study, we tested whether chronic pre-MI administration of TMZ would be beneficial during and after acute MI. Two-hundred male Wistar rats were studied in four groups: sham + TMZ diet (n = 20), sham + control diet (n = 20), MI + TMZ diet (n = 80), and MI + control diet (n = 80) splitted into one short-term and one long-term experiments. Sham surgery consisted of a thoracotomy without coronary ligation. MI was induced by coronary occlusion followed by reperfusion. Left ventricle (LV) function and remodeling were assessed by serial echocardiography throughout a 24-week post-MI period. LV remodeling was also assessed by quantitative histological analysis of post-MI scar formation at 24 weeks post-MI. During the short-term experiment, 10/80 rats died after MI, with no difference between groups (MI + control = 7/40, MI + TMZ = 3/40, P = 0.3). In the long-term experiment, the deaths occurred irregularly over the 24 weeks with no difference between groups (MI + control = 16% mortality, MI + TMZ = 17%, P = 0.8). There was no difference between groups as regard to LV ejection fraction (MI + control = 36 +/- 13%, MI + TMZ = 35 +/- 13%, P = 0.6). In this experimental model, TMZ had no effects on the post-MI occurrence of LV dysfunction or remodeling. Further investigations are warranted to assess whether the partial inhibition of fatty acid oxidation may limit the ability of the heart to respond to acute severe stress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20030737     DOI: 10.1111/j.1472-8206.2009.00802.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

Review 1.  Modulating fatty acid oxidation in heart failure.

Authors:  Vincenzo Lionetti; William C Stanley; Fabio A Recchia
Journal:  Cardiovasc Res       Date:  2011-02-02       Impact factor: 10.787

2.  ["Why is it always the heart which suffers from myocardial infarction?" The "Marburg hypothesis" of the pathogenesis of atherosclerosis].

Authors:  In Frau Susanne Memoriam Klumpp; Jürgen R Schaefer; Birgit Hufnagel; Bernhard Maisch; Josef Krieglstein
Journal:  Herz       Date:  2010-05       Impact factor: 1.443

Review 3.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

Review 4.  Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.

Authors:  Charissa E van den Brom; Carolien Se Bulte; Stephan A Loer; R Arthur Bouwman; Christa Boer
Journal:  Cardiovasc Diabetol       Date:  2013-03-04       Impact factor: 9.951

5.  Effect of Ginkgo biloba extract on experimental cardiac remodeling.

Authors:  Wei Li; Zhenhua Luo; Xingde Liu; Lingyun Fu; Yini Xu; Lirong Wu; Xianchun Shen
Journal:  BMC Complement Altern Med       Date:  2015-08-13       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.